Theratechnologies Stock Beta
| THTX Stock | USD 1.21 0.01 0.82% |
Theratechnologies fundamentals help investors to digest information that contributes to Theratechnologies' financial success or failures. It also enables traders to predict the movement of Theratechnologies Stock. The fundamental analysis module provides a way to measure Theratechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Theratechnologies stock.
Theratechnologies |
Theratechnologies Company Beta Analysis
Theratechnologies' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Theratechnologies Beta | 1.73 |
Most of Theratechnologies' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Theratechnologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Theratechnologies has a Beta of 1.725. This is 100.58% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Theratechnologies Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Theratechnologies' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Theratechnologies could also be used in its relative valuation, which is a method of valuing Theratechnologies by comparing valuation metrics of similar companies.Theratechnologies is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Theratechnologies will likely underperform.
Theratechnologies Fundamentals
| Return On Equity | -11.17 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 74.98 M | ||||
| Shares Outstanding | 45.98 M | ||||
| Shares Owned By Insiders | 1.22 % | ||||
| Shares Owned By Institutions | 51.56 % | ||||
| Number Of Shares Shorted | 43.03 K | ||||
| Price To Book | 20.13 X | ||||
| Price To Sales | 0.67 X | ||||
| Revenue | 81.76 M | ||||
| Gross Profit | 56.22 M | ||||
| EBITDA | (10.31 M) | ||||
| Net Income | (23.96 M) | ||||
| Cash And Equivalents | 36.46 M | ||||
| Cash Per Share | 0.38 X | ||||
| Total Debt | 58.97 M | ||||
| Debt To Equity | 5.62 % | ||||
| Current Ratio | 1.04 X | ||||
| Book Value Per Share | (0.43) X | ||||
| Cash Flow From Operations | (5.68 M) | ||||
| Short Ratio | 0.95 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Target Price | 5.26 | ||||
| Number Of Employees | 103 | ||||
| Beta | 1.73 | ||||
| Market Capitalization | 56.1 M | ||||
| Total Asset | 77.77 M | ||||
| Retained Earnings | (408.66 M) | ||||
| Working Capital | 16 M | ||||
| Net Asset | 77.77 M |
About Theratechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Theratechnologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theratechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theratechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Theratechnologies Stock Analysis
When running Theratechnologies' price analysis, check to measure Theratechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theratechnologies is operating at the current time. Most of Theratechnologies' value examination focuses on studying past and present price action to predict the probability of Theratechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theratechnologies' price. Additionally, you may evaluate how the addition of Theratechnologies to your portfolios can decrease your overall portfolio volatility.